









市場行情
/
股票
/
nasdaq-zyme
/

Zymeworks Inc

ZYME

26.860USD

+0.070+0.26%

收盤 12/24, 13:00（美東）報價延遲15分鐘

2.03B總市值

虧損本益比TTM



Zymeworks Inc

26.860

+0.070+0.26%

概覽公司財務分析

概覽

公司

財務

分析

關於 Zymeworks Inc 公司

Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.

Zymeworks Inc簡介



公司代碼ZYME

公司名稱Zymeworks Inc

上市日期Jun 24, 2019

CEOGalbraith (Kenneth H)

員工數量280

證券類型Ordinary Share

年結日Jun 24

公司地址108 Patriot Drive, Suite A

城市MIDDLETOWN

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編19709

電話13022748744

網址https://www.zymeworks.com/

公司代碼ZYME

上市日期Jun 24, 2019

CEOGalbraith (Kenneth H)

Zymeworks Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Mr. Robert E. (Bob) Landry

Independent Director

Mr. Gregory A. Ciongoli

Independent Director

Dr. Kelvin M. Neu ,M.D.

Independent Director

Mr. Scott Platshon

Acting Chief Investment Officer

Dr. Alessandra Cesano, M.D., Ph.D.

Independent Director

Ms. Leone D. Patterson, CPA

Chief Financial Officer, Chief Business Officer, Executive Vice President

Mr. Kenneth H. (Ken) Galbraith

Chairman of the Board, President, Chief Executive Officer

Mr. Carlos E. Campoy

Independent Director

Dr. Susan M. (Sue) Mahony, Ph.D.

Lead Independent Director

Mr. Oleg Nodelman

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Mr. Robert E. (Bob) Landry

Independent Director

Mr. Gregory A. Ciongoli

Independent Director

Dr. Kelvin M. Neu ,M.D.

Independent Director

Mr. Scott Platshon

Acting Chief Investment Officer

Dr. Alessandra Cesano, M.D., Ph.D.

Independent Director

Ms. Leone D. Patterson, CPA

Chief Financial Officer, Chief Business Officer, Executive Vice President

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月16日週日

持股股東

股東類型

持股股東

佔比

EcoR1 Capital, LLC

30.69%

Rubric Capital Management LP

6.29%

BVF Partners L.P.

5.26%

Morgan Stanley & Co. LLC

5.23%

Redmile Group, LLC

4.95%

其他

47.56%

持股股東

佔比

EcoR1 Capital, LLC

30.69%

Rubric Capital Management LP

6.29%

BVF Partners L.P.

5.26%

Morgan Stanley & Co. LLC

5.23%

Redmile Group, LLC

4.95%

其他

47.56%

股東類型

持股股東

佔比

Investment Advisor/Hedge Fund

51.37%

Investment Advisor

19.68%

Hedge Fund

18.70%

Research Firm

6.53%

Private Equity

2.79%

Individual Investor

0.88%

Pension Fund

0.31%

Venture Capital

0.28%

Sovereign Wealth Fund

0.27%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

390

74.41M

99.43%

-2.56M

2025Q2

383

76.90M

102.73%

+2.83M

2025Q1

400

71.70M

97.61%

-1.37M

2024Q4

389

68.69M

99.73%

-8.79M

2024Q3

388

74.13M

105.03%

-25.13M

2024Q2

387

74.77M

106.29%

-27.88M

2024Q1

389

74.54M

106.20%

-28.73M

2023Q4

388

72.09M

103.65%

-29.69M

2023Q3

376

69.54M

103.06%

-33.91M

2023Q2

364

70.30M

109.70%

-27.74M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

EcoR1 Capital, LLC

22.97M

30.56%

+5.09M

+28.44%

Jun 30, 2025

Rubric Capital Management LP

4.71M

6.27%

+372.11K

+8.58%

Jun 30, 2025

BVF Partners L.P.

4.31M

5.73%

Jun 30, 2025

Morgan Stanley & Co. LLC

3.62M

4.82%

+317.19K

+9.60%

Jun 30, 2025

Redmile Group, LLC

4.15M

5.52%

-638.32K

-13.33%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

3.11M

4.14%

-287.50K

-8.46%

Jun 30, 2025

The Vanguard Group, Inc.

2.46M

3.27%

+694.76K

+39.45%

Jun 30, 2025

Perceptive Advisors LLC

1.28M

1.7%

-589.40K

-31.61%

Jun 30, 2025

Vestal Point Capital, LP

1.15M

1.53%

+650.00K

+130.00%

Jun 30, 2025

Blackstone Alternative Asset Management, L.P.

1.66M

2.2%

+274.20K

+19.83%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

Tema Oncology ETF

2.25%

Virtus LifeSci Biotech Clinical Trials ETF

0.99%

ProShares Ultra Nasdaq Biotechnology

0.24%

iShares Micro-Cap ETF

0.18%

Federated Hermes MDT Small Cap Core ETF

0.15%

WisdomTree US SmallCap Quality Growth Fund

0.15%

SPDR S&P International Small Cap ETF

0.14%

Invesco Nasdaq Biotechnology ETF

0.14%

iShares Biotechnology ETF

0.12%

iShares MSCI USA Small-Cap Min Vol Factor ETF

0.12%

Tema Oncology ETF

佔比2.25%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.99%

ProShares Ultra Nasdaq Biotechnology

佔比0.24%

iShares Micro-Cap ETF

佔比0.18%

Federated Hermes MDT Small Cap Core ETF

佔比0.15%

WisdomTree US SmallCap Quality Growth Fund

佔比0.15%

SPDR S&P International Small Cap ETF

佔比0.14%

Invesco Nasdaq Biotechnology ETF

佔比0.14%

iShares Biotechnology ETF

佔比0.12%

iShares MSCI USA Small-Cap Min Vol Factor ETF

佔比0.12%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Zymeworks Inc的前五大股東是誰？



Zymeworks Inc的前五大股東如下：
EcoR1 Capital, LLC
持有股份：22.97M
佔總股份比例：30.56%。
Rubric Capital Management LP
持有股份：4.71M
佔總股份比例：6.27%。
BVF Partners L.P.
持有股份：4.31M
佔總股份比例：5.73%。
Morgan Stanley & Co. LLC
持有股份：3.62M
佔總股份比例：4.82%。
Redmile Group, LLC
持有股份：4.15M
佔總股份比例：5.52%。